← Eichor
Study identifier: NCT07698769 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial Environment

Condition: Mucosal Cytokine Profile of Patients (Type I and III Interferons, Pro-inflammatory Cytokines)  ·  Sponsor: Centre Hospitalier Intercommunal Creteil

PhaseN/A
Planned participants110
Who can joinAll sexes, 0 Months to 6 Months
Healthy volunteersNo

About this study

Among children aged ≤ 6 months included in the ENVIE study, the ENVIE\_ancillaire study will be offered to cases of RSV infection or to controls. The study involves a nasopharyngeal swab using a FLOQ-SWAB™ swab and a fingertip sample (dextro type). These samples will be collected specifically for the purpose of studying immunity. A blood sample may also be requested for children weighing ≥5 kg who are included in the ENVIE\_ancillaire study. The purpose of this sample collection will be to conduct an advanced immunological study

This description comes directly from the study's public registry record.

Talk to the study team

Julie TOUBIANA, PhD  ·  01 44 49 57 44  ·  julie.toubiana@aphp.fr

Camille JUNG, PhD  ·  0157022268  ·  camille.jung@chicreteil.fr

Always discuss trial participation with your own doctor first.

Locations (3)

CHI CréteilCréteil, FranceRecruiting
CHU NeckerParis, FranceRecruiting
CHU Robert-DebréParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07698769